原创力文档Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix. is it cost-effective外文翻译.PDFVIP
- 1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
- 2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
- 4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
- 5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传，每下载1次， 网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
Gynecologic Oncology 136 (2015) 43–47
Contents lists available at ScienceDirect
Gynecologic Oncology
journa l h omepage: /locate/ygyno
Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the
☆
cervix: Is it cost-effective?
Neil T. Phippen a,⁎, Charles A. Leath III b, Laura J. Havrilesky c, Jason C. Barnett d
a Gynecologic Oncology Service, Walter Reed National Military Medical Center, Room 3440, 3rdfl oor, Gyn Bldg 19, 8901 Wisconsin Ave, Bethesda, MD 20889, USA
b Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama School of Medicine, Room 10250, 1700 6th Avenue South, Birmingham, AL 35233, USA
c Division of Gynecologic Oncology, Duke Cancer Center, 20 Duke Medicine Circle, Durham, NC 27710, USA
d Division of Gynecologic Oncology, Department of OB/GYN, San Antonio Military Medical Center, 3551 Roger Brooke Drive, Fort Sam, Houston, TX 78234, USA
H I G H L I G H T S
• Bevacizumab plus paclitaxel and cisplatin in advanced, recurrent or persistent cervix cancer has an ICER/QALY of $155K.
• Bevacizumab use in this setting is more cost-effective than in any other gynecologic malignancy to date.
• Marginally discounting the cost of bevacizumab by N 37.5% results in an ICER/QALY of $100K.
a r t i c l e i n f o a b s t r a c t
Article history: Objective. Evaluate the cost-effectiveness of incorporating bevacizumab into the treatment regimen for
Received 12 August 2014 recurrent, persistent, or advanced stage carcinoma of the cervix following publicatio
您可能关注的文档
- 【Bluejc#3 延伸阅读】 Interpreting the results of cost-effectiveness studies外文翻译.pdf
- 1.the cost of capital外文翻译.pdf
- 2.1The Cost of Capital外文翻译.pdf
- 2D-Modeling and Development of Interdigitated Back Contact Solar Cells on Low-Cost Substrates外文翻译.pdf
- 2-The Problem of Social Cost外文翻译.pdf
- 3 The Welfare Cost of Monopply in Australia外文翻译.pdf
- 189.A Transaction Cost Theory of Politics189.政治交易成本理论.pdf
- 2013 srep：Plasmonic Amplification with Ultra-High Optical Gain at Room Temperature外文翻译.pdf
- A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada外文翻译.PDF
- A Low-cost and High Efficiency Architecture of AES Crypto-engine外文翻译.pdf
- Blind Bedside Placement of Postpyloric Feeding Tubes by Registered Dietitians. Success Rates, Outcomes, and Cost-Effectiveness外文翻译.PDF
- Carbon dioxide extraction from air is it an option外文翻译.pdf
- Case 3 - Cost of Capital at Ameritrade案例3-Ameritrade的资本成本.pdf
- Chapter 11, Group Cost of Living Indexes, Approximations and Axiomatics外文翻译.pdf
- chapter 17 Investing in Convertibles, Preferred Stocks,外文翻译.pdf
- coase - the problem of social cost外文翻译.pdf
- Coase 1960 The Problem of Social Cost外文翻译.pdf
- Corn at Interest The Extent and Cost of Grain Storage in Medieval England外文翻译.pdf
- Corporate derivatives use and the cost of equity外文翻译.pdf
- Cost Effective 3D-Printing of Visibly Transparent外文翻译.pdf
文档评论（0）